No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRCT240517P60000
- 0.60
- -0.55-47.83%
15min DelayClose May 9 15:59 ET
0.60High0.60Low
0.60Open1.15Pre Close4 Volume67 Open Interest60.00Strike Price240.00Turnover51.22%IV-5.87%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.60Time Value100Contract SizeAmericanOptions Type-0.2415Delta0.0660Gamma90.00Leverage Ratio-0.0938Theta-0.0032Rho-21.73Eff Leverage0.0288Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $67 to $75.
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Springworks Therapeutics (SWTX) and Omnicell (OMCL)